Editor-in-Chief Ufuk Demirkılıç Frequency Quarterly Abbreviation Turk J Vasc Surg Publisher Turkish National Vascular and Endovascular Surgery Society ISSN 2667-4947 E-ISSN 2667-5080

Turkish Journal of Vascular Surgery 2021 , Vol 30 , Issue 1
How to deal with chronic thromboembolic pulmonary arterial hypertension (CTEPH) during the COVID-19 pandemic: Too many gray zones to be considered
Tankut Akay1, Leyla Elif Sade2, Şerife Bozbaş3, Koray Hekimoğlu4, Kaan Okyay2, Bahadır Gültekin1, Sarp Beyazpınar1, Eren Günertem1, Anar Aliyev1, Atilla Sezgin1
1Department of Cardiovascular Surgery, Başkent University Faculty of Medicine, Ankara, Turkey
2Department of Cardiology, Başkent University Faculty of Medicine, Ankara, Turkey
3Department of Pulmonology, Başkent University Faculty of Medicine, Ankara, Turkey
4Department of Radiology, Başkent University Faculty of Medicine, Ankara, Turkey
DOI : 10.9739/tjvs.2020.748 In December 2019, a serious number of patients with pneumonia was first announced in Wuhan and, since March 11, 2020, the World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-2019) caused by SARS-CoV-2 to be a pandemic and a very severe global health problem. Severity about this disease is associated with an increasing age and comorbidities such as chronic heart and lung disease. Chronic thromboembolic pulmonary hypertension (CTEPH), another important and fatal disease, is a specific type of pulmonary hypertension characterized by obstruction or occlusion of subsegmental, segmental, or larger pulmonary arteries by the post-embolic fibrotic material which has a definitive cure by pulmonary endarterectomy performed under cardiopulmonary bypass and total circulatory arrest. In this article, we examined thoroughly and enlightened some of the gray zones in CTEPH patients for healthcare providers with the aim of providing a reasonable algorithm in the era of COVID-19 pandemic. Keywords : COVID-19, pandemic, pulmonary heart disease
Viewed : 1675
Downloaded : 571